PD-1/PD-L1信号通路及其在肿瘤中的应用  

PD-1/PD-L1 signaling pathway and its application in tumor

作　　者：王师[1,2] 罗龙龙[2] 吕明[2] 马远方[1] 

机构地区：[1]河南大学医学院细胞与分子免疫学实验室,开封475004 [2]军事医学科学院基础医学研究所免疫研究室,北京100850

出　　处：《国际药学研究杂志》2015年第2期143-147,共5页Journal of International Pharmaceutical Research

摘　　要：程序性死亡受体(PD)-1/PD-L1信号通路作为T细胞免疫反应的协同刺激信号通路,在适应性免疫中发挥着重要的作用。PD-1是一种主要表达在T细胞上的共受体,与其配体(PD-L1,PD-L2)结合能够抑制T细胞的活化,使机体免受自身免疫系统的攻击。除了调节并维持自身免疫耐受,在肿瘤细胞中PD-L1的表达上调,而在被病毒感染的T细胞中PD-1的表达也会上调,PD-1/PD-L1参与了肿瘤细胞及传染性病原体的免疫逃逸,因此阻断PD-1/PD-L1信号通路已成为肿瘤和慢性传染病研究的热点。目前,已经有多个抗PD-1、PD-L1单克隆抗体被FDA批准进入临床试验,用于癌症的治疗,疗效显著。PD-1 / PD-L1 signaling pathway as a T cell immune response co-stimulatory signaling pathway plays an important role in adaptive immunity. PD-1 is a major co-receptor expressing on T cells, binding with its ligands （PD-L1 and PD-L2）, PD-1 can inhibit T cell activation and protect the body against the attacks from its own immune system. In addition to adjusting and maintaining autoimmune tolerance, in tumor cells PD-L1 expression is up-regulated, while in the virus-infected T cells PD-L1 expression is also upregulated. PD-1 / PD-L1 are involved in the tumor and infectious pathogen immune evasion, thus blocking the PD-1 / PD-L1 signaling pathway has become a hot research of cancer and chronic diseases. Currently, there are several anti-PD-1 or PD-L1 monoelonal antibodies approved by the FDA to enter clinical studies, which have shown significant anti-cancer effect.

关 键 词：程序性死亡受体-1 程序性死亡受体-L1 信号通路 单克隆抗体 

分 类 号：R730.5[医药卫生—肿瘤]